Related Experiment Videos
Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement
1Division of Rheumatology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Abstract:
Membrane cofactor protein (MCP; CD46) is a widely distributed C3b/C4b-binding glycoprotein that inhibits complement activation on host cells. MCP is expressed primarily as four isoforms that arise by alternative splicing of a single gene. The differences reside in the domains for O-glycosylation and cytoplasmic tails. Tissue-specific expression of isoforms and the differential processing of precursors mediated by the cytoplasmic tails suggest that isoform variations are biologically significant. The goal of these experiments was to characterize the complement inhibitory profile of the four commonly expressed isoforms. The MCP isoforms (BC) with a larger O-glycosylation domain bound C4b more efficiently than the C isoforms, which are smaller and less glycosylated in this region. Additionally, cytoprotection assays of individual clones of transfected isoforms bearing equivalent copy numbers demonstrated that the BC isoforms also provided enhanced protection in a classical pathway-mediated system and cleaved cell-bound C4b more efficiently than the C isoforms. Taken together, these data demonstrate that BC isoforms preferentially protect against the classical pathway of complement. Such findings indicate a physiologic role for isoform variation and have therapeutic implications for use of MCP isoforms as complement inhibitors in such areas as xenotransplantation.
Insights
Membrane cofactor protein (MCP; CD46) isoforms BC offer superior protection against complement activation via the classical pathway. These findings highlight the biological significance of MCP isoform variation and its therapeutic potential.
Area of Science:
- Immunology
- Molecular Biology
Background:
- Membrane cofactor protein (MCP; CD46) is a key regulator of complement activation on host cells.
- MCP exists as four main isoforms generated by alternative splicing, differing in O-glycosylation domains and cytoplasmic tails.
Purpose of the Study:
- To characterize the complement inhibitory profiles of the four common MCP isoforms.
- To determine the functional significance of isoform-specific differences in O-glycosylation and cytoplasmic tails.
Main Methods:
- Comparison of C4b binding affinities across MCP isoforms.
- Cytoprotection assays using transfected isoforms with equivalent copy numbers.
- Assessment of C4b cleavage efficiency by individual MCP isoforms.
Main Results:
- MCP isoforms (BC) with larger O-glycosylation domains exhibited higher C4b binding efficiency compared to smaller, less glycosylated C isoforms.
- BC isoforms provided enhanced cytoprotection in classical pathway-mediated complement activation.
- BC isoforms demonstrated more efficient cleavage of cell-bound C4b than C isoforms.
Conclusions:
- MCP BC isoforms preferentially inhibit the classical pathway of complement activation.
- Isoform variation in MCP plays a significant physiological role in complement regulation.
- MCP isoforms hold therapeutic potential as complement inhibitors, particularly in xenotransplantation.